IFNB1 and myeloid sarcoma: The proportion of patients who received immunomodulating therapy was not statistically different between NMO and MS patients (33% in NMO, 1 patient with interferon beta and 3 with oral prednisolone; 21% in MS, 4 patients with interferon beta and 1 with oral prednisolone).